(PDF) Prm134 - Using Adjusted Indirect Comparison in Hta to

Prm134 - Using Adjusted Indirect Comparison in Hta to Overcome Short Follow-Up Time in Regulatory Randomized Controled Clinical Trials: Ribociclib as First-Line Therapy for Hr-Positive, Advanced Breast Cancer

Value in Health - United Kingdom

doi 10.1016/j.jval.2018.09.2254

Full Text

Open PDF

Abstract

Available in full text

Date

October 1, 2018

Authors

V Andreozzi

B Vandewalle

J FÃ©lix

Publisher

Elsevier BV

Related search

Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer

English

Pharmacoeconomic Analysis of Using Cyclin-Dependent Kinase 4 and 6 Inhibitors in the First Line Treatment of HR-positive HER2-negative Advanced Breast Cancer

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

2020

English

Pcn81 - Budget Impact Analysis of Cdk4/6 Inhibitors for the First Line Theraphy of Hr-Positive Her2-Negative Advanced Breast Cancer in the Russian Federation

English

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Geburtshilfe und Frauenheilkunde

English

Pcn171 - A Cost-Utility Analysis of Fulvestrant Versus Anastrozole as First-Line Therapy for Oestrogen Receptor-Positive Locally Advanced and Metastatic Breast Cancer

English

Reasons for Accepting or Declining to Participate in Randomized Clinical Trials for Cancer Therapy

British Journal of Cancer

Cancer Research

Oncology

2000

English

Pembrolizumab as First-Line Therapy in Programmed Death Ligand 1-Positive Advanced Lung Cancer: Is It as Effective as We Think It Is?

English

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus as First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Journal of Clinical Oncology

English

Prm258 - Methodological Approaches for Conducting Matching-Adjusted Indirect Comparisons Involving Multiple Randomized Controlled Trials

English

Amanote Research

Prm134 - Using Adjusted Indirect Comparison in Hta to Overcome Short Follow-Up Time in Regulatory Randomized Controled Clinical Trials: Ribociclib as First-Line Therapy for Hr-Positive, Advanced Breast Cancer

Value in Health - United Kingdom

doi 10.1016/j.jval.2018.09.2254

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer

Pharmacoeconomic Analysis of Using Cyclin-Dependent Kinase 4 and 6 Inhibitors in the First Line Treatment of HR-positive HER2-negative Advanced Breast Cancer

Pcn81 - Budget Impact Analysis of Cdk4/6 Inhibitors for the First Line Theraphy of Hr-Positive Her2-Negative Advanced Breast Cancer in the Russian Federation

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Pcn171 - A Cost-Utility Analysis of Fulvestrant Versus Anastrozole as First-Line Therapy for Oestrogen Receptor-Positive Locally Advanced and Metastatic Breast Cancer

Reasons for Accepting or Declining to Participate in Randomized Clinical Trials for Cancer Therapy

Pembrolizumab as First-Line Therapy in Programmed Death Ligand 1-Positive Advanced Lung Cancer: Is It as Effective as We Think It Is?

Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus as First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Prm258 - Methodological Approaches for Conducting Matching-Adjusted Indirect Comparisons Involving Multiple Randomized Controlled Trials